6 March 2018 - - Foster City, California-based global research-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has released results from a preclinical study evaluating the combination of a proprietary investigational oral toll-like receptor 7 agonist, GS-9620, and a proprietary investigational broadly neutralising antibody, PGT121, as part of a human immunodeficiency virus (HIV) eradication strategy, the company said.
The study was conducted in collaboration with researchers at Beth Israel Deaconess Medical Center.
Data from the study carried out in simian-HIV (SHIV)-infected rhesus monkeys on suppressive antiretroviral therapy (ART) demonstrated that a combination treatment of GS-9620 and PGT121 resulted in a subset of animals maintaining viral suppression after ART discontinuation.
These data, discussed during a press conference at the 2018 Conference on Retroviruses and Opportunistic Infection in Boston, support further clinical investigation of combination strategies involving bNAbs and a TLR7 agonist which may have the potential to achieve long-term viral suppression without the need for daily ART.
Gilead Sciences discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 40 countries worldwide.